3B Blackbio DX Ltd
3B Blackbio DX Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on 3B Blackbio DX Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. EBITDA for Q2 FY 2024-25: ₹1,929.17 lakh, up from ₹1,059.54 lakh in Q2 FY 2023-24.
From 3B Blackbio DX Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. +48.5% YoY).
- Diagnostic division (3B BlackBio + TRUPCR Europe) Q2 revenue: ₹2,457.55 lakh vs ₹1,465.63 lakh in Q2 FY 2023-24 (approx. +67.6% YoY).
- Export sales (non-COVID) in Q2 FY 2024-25: ₹366.50 lakh vs ₹170.17 lakh in Q2 FY 2023-24 (approx. +115% YoY).
- TRUPCR Europe Ltd. (Manchester site) Q2 sales grew by 51% YoY to ₹404,900 GBP.
- Molecular diagnostic sales for standalone 3B: ₹2,194.18 lakh in Q2 FY 2024-25 vs ₹1,410.19 lakh in Q2 FY 2023-24 (approx. +55.6% YoY).
- Revenue spike from seasonal Flu, Dengue & Chikungunya in Q2 2024-25 contributed extra growth (~28%), expected not to continue in Q3/Q4.
2 more points management made on revenue & sales performance
Profitability & Margins
See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 40).
- Looking for inorganic growth via acquisition since FY22; will pursue only if it meets internal IRR criteria; may consider share buyback if acquisition candidate not found (Page 40).
- Deployment of some funds planned in joint venture created in Manchester, UK, depending on need (Page 40).
- No specific capex amounts, project timelines, or plant locations explicitly mentioned in the presentation.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What 3B Blackbio DX Ltd's management said in earlier quarters
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q2 FY25 results?
Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. EBITDA for Q2 FY 2024-25: ₹1,929.17 lakh, up from ₹1,059.54 lakh in Q2 FY 2023-24.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 40).
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.